维普中文期刊产品整合服务
15篇 您的检索式:作者名="Chambers SD"
    题名 作者 年代 出处 被引量
1KRAS and BRAF mutations in advanced colorectal cancer areassociated with poor prognosis but do not precludebenefit from oxaliplatin or irinotecan: results fromthe MRC FOCUS trial 显示文摘Richman SD Seymour MT Chambers P 2009J Clin Oncol2009,27,:1
2KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan:results from the MRC FOCUS trial显示文摘Richman SD Seymour MT Chambers P 2009J Clin Oncol2009,27,:1
3KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan:results from the MRC FOCUS trial显示文摘Richman SD Seymour MT Chambers P 0,,35:1
4Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing显示文摘Richman SD Chambers P Seymour MT 0,,:1
5STAT5 is required for thymopoiesis in a development stage-specific manner显示文摘Kang J DiBenedetto B Narayan K Zhao H Der SD Chambers CA 2004J Immunol2004,173,4:1
6KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial显示文摘Richman SD Seymour MT Chambers P 2009J Clin Oncol2009,27,35:1
7Partial liquid ventilation improves gas exchange and increases EELV in acute lung injury显示文摘Gauger PG Overbeck MC Chambers SD 1998J Appl Physiol1998,84,:1
8KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan:results from the MRC FOCUS trial显示文摘Richman SD Seymour MT Chambers P 2009J Clin Oncol2009,27,35:1
9Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of muhiple sample testing 显示文摘Richman SD Chambers P Seymour MT 2011Anal Cell Pathol ( Amst )2011,34,12:1
10Partial liquid ventilation improves gas exchange and increases EELV in acute lung injury 显示文摘Gauger PG Overbeck MC Chambers SD 1998J Appl Physiol1998,84,2:1
11KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial显示文摘Richman SD Seymour MT Chambers P 2009J Clin Oncol2009,27,35:1
12Acute tonal failure in Kawasaki disease显示文摘Mac Ardle BM Chambers TL Weller SD 1983J Royal Soc Med1983,76,7:1
13KRAS and BRAF mutation in advanced colorectal cancer are associated with poor prognosis but do not preclude bene- fit from Oxaliplatin or Irinotecan: results from the MRC FOCUS Trial显示文摘Richman SD Seymour MT Chambers P 2009J Clin Oncol2009,27,35:1
14Determination of the in vivo cavitation nuclei characteristics of blood显示文摘Chambers SD Bartlett RH Ceccio SL 1999ASAIO J1999,45,6:1
15KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan:results from the MRC FOCUS trial显示文摘Richman SD Seymour MT Chambers P 0,,35:1
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费